---
title: Anticoagulants and Antiplatelet Agents
type: content
phase: 1
status: complete
priority: high
tags: [anticoagulants, warfarin, heparin, DOACs, antiplatelet, aspirin, clopidogrel, thrombosis, bleeding]
created: 2025-11-08
last_modified: 2025-11-08
---

# Anticoagulants and Antiplatelet Agents

## Introduction

Thromboembolic disorders are major causes of morbidity and mortality. Anticoagulant and antiplatelet drugs prevent and treat pathological thrombus formation while balancing the risk of bleeding. Understanding the coagulation cascade, drug mechanisms, and monitoring is essential for safe, effective therapy.

## Core Concept

**Hemostasis involves**:
1. **Primary hemostasis**: Platelet adhesion, activation, aggregation → platelet plug
2. **Secondary hemostasis**: Coagulation cascade → fibrin clot
3. **Fibrinolysis**: Clot breakdown

**Antithrombotic drugs target**:
- **Antiplatelet agents**: Inhibit platelet function (arterial thrombosis)
- **Anticoagulants**: Inhibit coagulation factors (venous thrombosis)
- **Fibrinolytics**: Dissolve formed clots

---

## Coagulation Cascade Overview

### Intrinsic Pathway
XII → XIIa → XI → XIa → IX → IXa (+ VIIIa) → **Common Pathway**

### Extrinsic Pathway
Tissue Factor + VII → VIIa → **Common Pathway**

### Common Pathway
X → Xa (+ Va) → **Prothrombin (II) → Thrombin (IIa)** → Fibrinogen → Fibrin

### Key Points
- **Thrombin (IIa)**: Central enzyme, converts fibrinogen to fibrin
- **Factor Xa**: Critical junction of pathways
- **Vitamin K-dependent factors**: II, VII, IX, X (+ Protein C, Protein S)
- **Calcium required**: For multiple steps

---

## Warfarin (Coumarin Anticoagulant)

### Mechanism of Action

**Primary Mechanism**:
- Inhibits **Vitamin K epoxide reductase (VKORC1)**
- Prevents regeneration of reduced vitamin K
- ↓Synthesis of vitamin K-dependent clotting factors:
  - **Factors II, VII, IX, X** (procoagulant)
  - **Protein C, Protein S** (anticoagulant)

**Time Course**:
- **Delayed onset** (days): Must wait for depletion of existing factors
- Factor VII (shortest t½ ~6 hr) depletes first → ↑PT/INR early
- Factor II (longest t½ ~60 hr) depletes last → full anticoagulation after 5-7 days
- **Initial pro-thrombotic period**: Protein C (t½ ~8 hr) depletes before Factor II
  - Risk of warfarin-induced skin necrosis
  - Bridge with heparin in high VTE risk patients

### Pharmacokinetics

**Absorption**: Oral, 100% bioavailability
**Onset**: PT prolonged in 1-3 days; full effect in 5-7 days
**Metabolism**: Hepatic (CYP2C9, CYP3A4, CYP1A2)
**Excretion**: Renal (metabolites)
**Half-life**: 36-42 hours (long)
**Racemic mixture**: S-enantiomer more potent (5×), metabolized by CYP2C9

### Clinical Indications

1. **Atrial fibrillation** (stroke prevention)
2. **Venous thromboembolism** (DVT/PE) - treatment and prophylaxis
3. **Mechanical heart valves** (lifelong anticoagulation)
4. **Thrombophilia** (Factor V Leiden, Protein C/S deficiency, etc.)
5. **Post-MI** (selected cases with LV thrombus)

### Dosing and Monitoring

**Initial Dosing**:
- Typical: 5 mg daily (lower in elderly, 2.5 mg)
- Adjust based on INR

**Monitoring: INR (International Normalized Ratio)**
```
INR = (PT patient / PT control)^ISI
```

**Target INR Ranges**:
- **AF, DVT/PE**: 2.0-3.0
- **Mechanical valves**:
  - Bileaflet aortic: 2.0-3.0
  - Mitral or older valves: 2.5-3.5

**Monitoring Frequency**:
- Initial: Daily to every few days
- Stable: Every 4 weeks
- After dose change: In 3-7 days

### Adverse Effects

**Bleeding** (most common):
- Major bleeding: 1-3% per year
- Any INR increases risk, especially >4
- Sites: GI, intracranial, genitourinary

**Warfarin-Induced Skin Necrosis** (rare, 0.1%):
- Days 3-5 of therapy
- Protein C depletion → microvascular thrombosis
- Necrosis of breast, buttocks, thighs
- Risk factors: Protein C/S deficiency, high loading doses
- Prevention: Bridge with heparin, start low dose

**Purple Toe Syndrome** (rare):
- Weeks after initiation
- Cholesterol microemboli
- Painful, purplish toes

**Teratogenicity**:
- **Pregnancy Category X**
- **Fetal warfarin syndrome**: Nasal hypoplasia, stippled epiphyses (6-12 weeks)
- CNS abnormalities (any trimester)
- Avoid in pregnancy

**Other**:
- Hair loss
- Osteoporosis (long-term)

### Drug Interactions (Extensive)

**Increase INR (↑bleeding risk)**:

*CYP2C9 Inhibitors*:
- Amiodarone, fluconazole, metronidazole
- Sulfonamides (TMP-SMX)
- Reduce warfarin dose 10-50%

*Decrease Vitamin K*:
- Antibiotics (↓gut flora synthesis)

*Displace from albumin*:
- Aspirin, NSAIDs

*Other*:
- Acetaminophen (chronic high dose)
- Cimetidine
- Allopurinol

**Decrease INR (↓anticoagulation)**:

*CYP Inducers*:
- Rifampin (potent)
- Carbamazepine, phenytoin, phenobarbital
- St. John's wort

*Increase Vitamin K*:
- Vitamin K-rich foods (kale, spinach, broccoli)
- Vitamin K supplements

*Decrease absorption*:
- Cholestyramine

**High-Risk Interactions**:
- **Amiodarone**: Reduce warfarin 30-50%
- **Rifampin**: May double warfarin requirement
- **Antibiotics**: Check INR more frequently

### Reversal and Management

**Non-Urgent (High INR, No Bleeding)**:
- **INR 4-10, no bleeding**: Hold dose, resume at lower dose when INR therapeutic
- **INR >10, no bleeding**: Hold dose, give **Vitamin K 2.5-5 mg PO**

**Urgent (Major Bleeding or Emergency Surgery)**:
- **4-Factor Prothrombin Complex Concentrate (PCC)**: 25-50 units/kg IV
  - Contains factors II, VII, IX, X
  - **Rapid reversal** (minutes)
  - Preferred over FFP
- **Vitamin K 10 mg IV** (slow infusion)
  - Takes 6-24 hours for effect
  - Give with PCC
- **Fresh Frozen Plasma (FFP)**: 10-15 mL/kg
  - If PCC unavailable
  - Slower, requires large volume

### Contraindications

**Absolute**:
- Pregnancy
- Active bleeding
- Severe thrombocytopenia
- Recent CNS/eye surgery
- Inability to monitor INR

**Relative**:
- Fall risk
- Severe hepatic disease
- Uncontrolled hypertension
- GI ulcers
- Medication non-adherence

### Pharmacogenomics

**CYP2C9 Polymorphisms**:
- *1 allele: Normal metabolizer
- *2, *3 alleles: Slow metabolizers → ↑warfarin sensitivity, ↑bleeding risk
- Dose reduction needed

**VKORC1 Polymorphisms**:
- -1639A variant: ↑warfarin sensitivity
- More common in Asians

**FDA-approved pharmacogenomic dosing algorithms** available

### Clinical Pearls

1. **Bridge with heparin**: In high VTE risk until INR therapeutic (≥2)
2. **INR fluctuations common**: Multiple drug and food interactions
3. **Frequent monitoring required**: Major limitation
4. **Mechanical valves**: Warfarin remains gold standard (DOACs contraindicated)
5. **Vitamin K intake**: Consistency, not avoidance
6. **Pregnancy**: Absolutely contraindicated
7. **Narrow therapeutic index**: Requires individualization

---

## Heparins

### Unfractionated Heparin (UFH)

**Mechanism of Action**:
- Activates **Antithrombin III (ATIII)**
- ATIII-heparin complex inactivates:
  - **Thrombin (IIa)** - requires long heparin chains
  - **Factor Xa** - requires shorter chains
  - Also: IXa, XIa, XIIa
- **Immediate anticoagulant effect**

**Pharmacokinetics**:
- **IV or SC** (NOT oral - large, charged molecule)
- **Immediate onset** (IV)
- Binds to plasma proteins → variable response
- Metabolism: Reticuloendothelial system + renal
- **Half-life**: 1-2 hours (dose-dependent)
- Does NOT cross placenta (safe in pregnancy)

**Clinical Indications**:
1. **Acute VTE** (DVT/PE)
2. **Acute coronary syndrome** (STEMI, NSTEMI, unstable angina)
3. **Cardiopulmonary bypass** (cardiac surgery)
4. **VTE prophylaxis** (hospitalized patients)
5. **Pregnancy** (anticoagulant of choice)
6. **Bridging** to/from warfarin
7. **Hemodialysis** (prevent clotting in circuit)

**Dosing**:

*Therapeutic (IV)*:
- **Loading**: 80 units/kg bolus
- **Infusion**: 18 units/kg/hr
- Adjust to aPTT

*Prophylactic (SC)*:
- 5000 units SC BID or TID

**Monitoring: aPTT (activated Partial Thromboplastin Time)**:
- **Target**: 1.5-2.5 × control (typically 60-80 seconds)
- Check: 6 hours after dose change, then daily
- Also monitor: Anti-Xa levels (alternative, more accurate)

**Advantages Over LMWH**:
- **Short half-life**: Easier to reverse, useful perioperatively
- **Renal clearance independent**: Safe in renal failure
- **Reversible with protamine**

**Adverse Effects**:

**Bleeding**:
- Most common adverse effect
- Risk factors: High dose, concomitant antiplatelet drugs, elderly, renal failure

**Heparin-Induced Thrombocytopenia (HIT)**:
- **Type I** (non-immune):
  - Days 1-4
  - Mild thrombocytopenia (>100k)
  - Non-immune, benign
  - Continue heparin
- **Type II** (immune-mediated):
  - **Days 5-14** (can occur earlier with recent heparin exposure)
  - **Antibodies against PF4-heparin complex**
  - Severe thrombocytopenia (<100k, often <50k)
  - **Paradoxical thrombosis** (arterial and venous)
  - **Mortality 20-30% if untreated**

  **4 T's Score** (assess HIT probability):
  - Thrombocytopenia
  - Timing
  - Thrombosis
  - oTher causes

  **Management**:
  - **Stop ALL heparin** (including flushes, LMWH)
  - Start **alternative anticoagulant**:
    - Argatroban (direct thrombin inhibitor)
    - Fondaparinux
    - DOAC
  - **Do NOT give warfarin alone** (limb gangrene risk)
  - **Do NOT give platelet transfusion**

**Osteoporosis**: Long-term use (>6 months)

**Hyperkalemia**: ↓Aldosterone synthesis

**Hypersensitivity**: Rare

**Reversal**:
- **Protamine sulfate**: 1 mg neutralizes 100 units heparin
  - Dose based on time since heparin
  - Max rate: 5 mg/min (risk of hypotension, bradycardia)
  - Adverse: Hypotension, anaphylaxis (fish allergy)

### Low Molecular Weight Heparins (LMWH)

**Drugs**: Enoxaparin, Dalteparin, Tinzaparin

**Mechanism**:
- Derived from UFH (depolymerization)
- Shorter chains (4,000-6,000 Da vs. 15,000 Da)
- **Preferentially inhibit Factor Xa** (thrombin inhibition requires long chains)
- Still requires antithrombin III

**Advantages Over UFH**:
- **Subcutaneous dosing** (outpatient use)
- **Predictable pharmacokinetics** (less protein binding)
- **No monitoring required** (in most cases)
- **Fixed dosing** (weight-based)
- **Longer half-life**: 4-6 hours (BID dosing)
- **Lower HIT risk**: ~10× less than UFH

**Clinical Indications**:
1. **VTE treatment** (outpatient DVT)
2. **VTE prophylaxis** (medical, surgical)
3. **Acute coronary syndrome**
4. **Pregnancy** (safe, doesn't cross placenta)
5. **Bridging** to warfarin (outpatient)

**Dosing (Enoxaparin)**:

*Therapeutic*:
- **VTE treatment**: 1 mg/kg SC q12h OR 1.5 mg/kg SC daily
- **ACS**: 1 mg/kg SC q12h

*Prophylactic*:
- **Medical**: 40 mg SC daily
- **Surgical**: 30 mg SC q12h OR 40 mg SC daily

**Dose Adjustment**:
- **Renal impairment (CrCl <30)**: Reduce dose 50% OR use UFH
  - Risk of accumulation
  - Consider anti-Xa monitoring

**Monitoring**:
- **Usually NOT required**
- Consider **anti-Xa levels** in:
  - Obesity (>150 kg)
  - Renal impairment
  - Pregnancy
  - Extremes of weight
- **Target anti-Xa**:
  - Therapeutic (q12h dosing): 0.6-1.0 units/mL (4 hrs post-dose)
  - Prophylactic: 0.2-0.4 units/mL

**Adverse Effects**:
- **Bleeding** (lower risk than UFH)
- **HIT** (lower risk than UFH, but possible)
- **Accumulation in renal failure**
- **Spinal hematoma** (with neuraxial anesthesia)

**Reversal**:
- **Protamine**: Partially effective (~60% reversal of anti-Xa activity)
  - 1 mg protamine per 1 mg enoxaparin (if <8 hrs since dose)
- **Andexanet alfa**: FDA-approved Factor Xa inhibitor reversal agent (expensive, limited availability)

**Contraindications**:
- Active bleeding
- Severe thrombocytopenia
- **Severe renal impairment** (relative, dose adjust or use UFH)

### Fondaparinux

**Mechanism**:
- **Synthetic pentasaccharide** (selective Factor Xa inhibitor)
- Binds antithrombin → selective inactivation of Xa
- **NO direct thrombin inhibition**

**Pharmacokinetics**:
- SC administration
- **100% bioavailability**
- **Long half-life**: 17-21 hours (once daily)
- **Renal excretion** (contraindicated if CrCl <30)
- Predictable dose response

**Clinical Indications**:
1. **VTE treatment and prophylaxis**
2. **Acute coronary syndrome**
3. **HIT** (alternative anticoagulant - does NOT cross-react)

**Dosing**:
- **VTE treatment**: Weight-based (5/7.5/10 mg SC daily)
  - <50 kg: 5 mg
  - 50-100 kg: 7.5 mg
  - >100 kg: 10 mg
- **VTE prophylaxis**: 2.5 mg SC daily

**Advantages**:
- **No HIT risk** (doesn't bind PF4)
- Predictable response
- Once daily dosing
- No monitoring

**Disadvantages**:
- **NO reversal agent**
- Renal elimination (avoid in renal failure)
- Long half-life (if bleeding occurs)

**Adverse Effects**:
- Bleeding
- Thrombocytopenia (rare, not HIT)

---

## Direct Oral Anticoagulants (DOACs)

**Classes**:
1. **Direct Thrombin (IIa) Inhibitors**: Dabigatran
2. **Direct Factor Xa Inhibitors**: Rivaroxaban, Apixaban, Edoxaban

### Advantages of DOACs

1. **Rapid onset** (hours)
2. **Predictable pharmacokinetics** (no monitoring)
3. **Fixed dosing** (no INR checks)
4. **Fewer drug interactions** than warfarin
5. **Fewer dietary restrictions**
6. **Lower ICH risk** vs. warfarin
7. **Shorter half-lives** (easier perioperative management)

### Limitations of DOACs

1. **Contraindicated in mechanical valves**
2. **Limited experience in pregnancy** (avoid)
3. **Cost** (no generic)
4. **Renal dose adjustments required**
5. **No routine monitoring** (can't assess compliance)
6. **Reversal agents** limited/expensive

### Dabigatran (Pradaxa)

**Mechanism**:
- **Direct thrombin (IIa) inhibitor**
- Reversibly binds active site
- Inhibits free and clot-bound thrombin

**Pharmacokinetics**:
- **Prodrug** (dabigatran etexilate)
- Oral, bioavailability 3-7% (food doesn't affect)
- **Peak**: 1-2 hours
- **Half-life**: 12-17 hours
- **80% renal excretion** (requires dose adjustment)
- **P-glycoprotein substrate**

**Clinical Indications**:
1. **Atrial fibrillation** (stroke prevention)
2. **VTE treatment and prophylaxis**

**Dosing**:
- **AF**: 150 mg BID (or 110 mg BID if age ≥80, CrCl 30-50)
- **VTE treatment**: 150 mg BID (after 5-10 days of parenteral anticoagulant)
- **VTE prophylaxis** (orthopedic surgery): 110 mg day 1, then 220 mg daily

**Dose Adjustment**:
- **CrCl 30-50**: Consider 110 mg BID
- **CrCl 15-30**: 75 mg BID (US only)
- **CrCl <15 or dialysis**: Contraindicated

**Adverse Effects**:
- **Bleeding** (similar to warfarin)
- **Dyspepsia/GI upset** (10-15%) - unique to dabigatran
  - Related to tartaric acid in capsule
- **Lower ICH risk** than warfarin
- **MI risk**: Slightly higher than warfarin (controversial)

**Drug Interactions**:
- **P-gp inhibitors** (dronedarone, ketoconazole): ↑dabigatran levels, avoid or ↓dose
- **P-gp inducers** (rifampin): ↓dabigatran levels, avoid

**Reversal**:
- **Idarucizumab (Praxbind)**: Specific reversal agent
  - Monoclonal antibody fragment
  - 5 g IV (two 2.5 g doses)
  - Immediate reversal
- **Hemodialysis**: Can remove (60% in 2-3 hours)

**Monitoring**:
- Usually not required
- If needed: **Thrombin time (TT)** or dilute TT, aPTT (less sensitive)

### Rivaroxaban (Xarelto)

**Mechanism**:
- **Direct Factor Xa inhibitor**
- Reversibly binds active site

**Pharmacokinetics**:
- Oral, bioavailability 80-100%
- **Take with food** (increases absorption of higher doses)
- **Peak**: 2-4 hours
- **Half-life**: 5-9 hours (young), 11-13 hours (elderly)
- Hepatic metabolism (CYP3A4) + renal excretion (33%)
- P-glycoprotein substrate

**Clinical Indications**:
1. **Atrial fibrillation**
2. **VTE treatment and prophylaxis**
3. **ACS** (with antiplatelet therapy)

**Dosing**:
- **AF**: 20 mg daily with dinner
- **VTE treatment**: 15 mg BID × 3 weeks, then 20 mg daily
- **VTE prophylaxis**: 10 mg daily

**Dose Adjustment**:
- **AF + CrCl 15-50**: 15 mg daily
- **CrCl <15**: Avoid

**Advantages**:
- **Once daily dosing** (for most indications)
- With or without food (10 mg); **with food** (15-20 mg doses)

**Reversal**:
- **Andexanet alfa (Andexxa)**: Factor Xa decoy, binds rivaroxaban
  - Low dose: 400 mg bolus + 4 mg/min × 120 min
  - High dose: 800 mg bolus + 8 mg/min × 120 min
  - Very expensive, limited availability

### Apixaban (Eliquis)

**Mechanism**:
- **Direct Factor Xa inhibitor**

**Pharmacokinetics**:
- Oral, bioavailability ~50%
- Can take without regard to food
- **Peak**: 3-4 hours
- **Half-life**: 12 hours
- Multiple elimination pathways (hepatic, renal, intestinal)
- **27% renal excretion** (safest in renal impairment)

**Clinical Indications**:
1. **Atrial fibrillation**
2. **VTE treatment and prophylaxis**

**Dosing**:
- **AF**: 5 mg BID
  - **Reduce to 2.5 mg BID** if ≥2 of:
    - Age ≥80
    - Weight ≤60 kg
    - SCr ≥1.5 mg/dL
- **VTE treatment**: 10 mg BID × 7 days, then 5 mg BID
- **VTE prophylaxis**: 2.5 mg BID

**Dose Adjustment**:
- **CrCl 15-29**: Use with caution
- **CrCl <15 or dialysis**: Avoid

**Advantages**:
- **BID dosing** (more consistent anticoagulation)
- **Least renal clearance** (safest in CKD)
- **No food requirement**
- **Lowest bleeding risk** in some studies

**Reversal**:
- **Andexanet alfa** (same as rivaroxaban)

### Edoxaban (Savaysa)

**Mechanism**:
- **Direct Factor Xa inhibitor**

**Pharmacokinetics**:
- Oral, bioavailability 62%
- **Peak**: 1-2 hours
- **Half-life**: 10-14 hours
- **50% renal excretion**

**Clinical Indications**:
1. **Atrial fibrillation**
2. **VTE treatment**

**Dosing**:
- **AF**: 60 mg daily
  - **Reduce to 30 mg** if CrCl 15-50, weight ≤60 kg, or P-gp inhibitors
- **VTE**: 60 mg daily (after 5-10 days parenteral anticoagulation)

**Unique Feature**:
- **Contraindicated if CrCl >95** in AF (paradoxically ↑stroke risk - increased renal clearance)

**Dose Adjustment**:
- **CrCl 15-50**: 30 mg daily
- **CrCl <15**: Not recommended

**Reversal**:
- **Andexanet alfa**

### DOAC Comparison Summary

| Feature | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
|---------|-----------|-------------|----------|----------|
| Target | Thrombin (IIa) | Factor Xa | Factor Xa | Factor Xa |
| Dosing | BID | Daily (AF) | BID | Daily |
| Renal excretion | 80% | 33% | 27% | 50% |
| Food requirement | No | Yes (high doses) | No | No |
| Reversal | Idarucizumab | Andexanet | Andexanet | Andexanet |
| Dyspepsia | Common | Rare | Rare | Rare |

### General DOAC Pearls

1. **Mechanical valves**: Contraindicated (use warfarin)
2. **Severe renal impairment**: Caution or avoid
3. **Perioperative**: Hold 1-2 days before (depends on bleed risk, renal function)
4. **Non-adherence detection**: Difficult (no routine monitoring)
5. **Pregnancy**: Avoid (limited data)
6. **Cost**: Significant barrier for some patients

---

## Antiplatelet Agents

### Aspirin (ASA)

**Mechanism**:
- **Irreversibly inhibits COX-1** (cyclooxygenase-1)
- ↓Thromboxane A2 (TXA2) synthesis in platelets
- Prevents platelet aggregation
- Effect lasts **platelet lifetime** (7-10 days)

**Pharmacokinetics**:
- Rapid absorption
- Peak: 30-40 minutes
- Platelet effect: Immediate, lasts 7-10 days

**Clinical Indications**:
1. **Acute coronary syndrome** (STEMI, NSTEMI, unstable angina)
2. **Primary prevention**: High CV risk patients
3. **Secondary prevention**: CAD, stroke, PAD
4. **Post-PCI** (with P2Y12 inhibitor = DAPT)
5. **Atrial fibrillation** (if can't take anticoagulant)

**Dosing**:
- **Acute MI**: 162-325 mg (chewed) loading, then 81-325 mg daily
- **Chronic**: 75-162 mg daily (usually 81 mg)
- **Post-PCI**: 81 mg daily (with P2Y12 inhibitor)

**Adverse Effects**:
- **GI upset, ulcers, bleeding**
- **Reye's syndrome** (children with viral illness)
- Hypersensitivity (asthma exacerbation, urticaria)
- Tinnitus (high doses)

**Contraindications**:
- Active bleeding
- Aspirin allergy
- Children with viral illness (Reye's syndrome)

**Clinical Pearls**:
1. **Chew in ACS**: Faster onset
2. **Low-dose effective**: 81 mg as effective as higher doses, less bleeding
3. **Primary prevention**: Benefits in high-risk patients, but reassess periodically
4. **Enteric-coated**: May reduce GI upset

### P2Y12 Inhibitors

**Mechanism**:
- Inhibit **ADP receptor P2Y12** on platelets
- Prevent ADP-mediated platelet activation and aggregation

#### Clopidogrel (Plavix)

**Mechanism**:
- **Prodrug** requiring CYP2C19 activation
- **Irreversible** P2Y12 inhibition
- Effect lasts platelet lifetime (7-10 days)

**Pharmacokinetics**:
- Prodrug: Requires CYP2C19 activation
- Onset: 2-6 hours
- Peak effect: 3-7 days (steady state)

**Clinical Indications**:
1. **Acute coronary syndrome** (with aspirin = DAPT)
2. **Post-PCI** (stent placement)
3. **Stroke/TIA**
4. **Peripheral arterial disease**
5. **Aspirin alternative** (if intolerant)

**Dosing**:
- **Loading**: 300-600 mg
- **Maintenance**: 75 mg daily
- **DAPT duration**: 6-12 months post-PCI (depends on stent type, bleed risk)

**Adverse Effects**:
- **Bleeding**
- **TTP** (thrombotic thrombocytopenic purpura) - rare (0.02%)
- GI upset

**Pharmacogenomics**:
- **CYP2C19 polymorphisms**:
  - Poor metabolizers (2-15% of population, varies by race)
  - ↓Clopidogrel activation → ↓efficacy → ↑CV events
  - Consider alternative (prasugrel, ticagrelor) in poor metabolizers

**Drug Interactions**:
- **PPIs** (especially omeprazole): May ↓clopidogrel activation
  - Use pantoprazole if PPI needed
- **CYP2C19 inhibitors**: ↓efficacy

#### Prasugrel (Effient)

**Advantages over Clopidogrel**:
- More rapid, potent, consistent platelet inhibition
- **NOT affected by CYP2C19 polymorphisms**

**Clinical Indications**:
- **ACS undergoing PCI** (more potent than clopidogrel)

**Dosing**:
- **Loading**: 60 mg
- **Maintenance**: 10 mg daily

**Adverse Effects**:
- **Higher bleeding risk** than clopidogrel
- Especially in: Age ≥75, weight <60 kg, history of stroke/TIA

**Contraindications**:
- History of stroke/TIA (↑ICH risk)
- Active bleeding

**Clinical Pearl**: **More potent** but **more bleeding** than clopidogrel; avoid if prior stroke

#### Ticagrelor (Brilinta)

**Unique Features**:
- **NOT a prodrug** (direct P2Y12 inhibitor)
- **Reversible** binding (unlike clopidogrel, prasugrel)
- **Faster onset and offset**

**Clinical Indications**:
- **ACS** (with or without PCI)

**Dosing**:
- **Loading**: 180 mg
- **Maintenance**: 90 mg BID
- **Aspirin dose**: Use ≤100 mg daily (higher doses ↓ticagrelor efficacy)

**Advantages**:
- More rapid onset/offset
- Not affected by CYP polymorphisms
- **Superior to clopidogrel** in ACS (PLATO trial)

**Adverse Effects**:
- **Dyspnea** (10-15%) - usually transient, mechanism unclear
- **Bleeding** (similar to prasugrel)
- Bradycardia (transient)
- Ventricular pauses

**Drug Interactions**:
- **Strong CYP3A4 inhibitors/inducers**: Avoid
- Maintain **aspirin ≤100 mg** daily

**Clinical Pearls**:
1. **Superior efficacy** vs. clopidogrel in ACS
2. **BID dosing**: Adherence concern
3. **Dyspnea common**: Usually self-limited
4. **Reversible**: Faster recovery of platelet function

### Glycoprotein IIb/IIIa Inhibitors

**Mechanism**:
- Block **GP IIb/IIIa receptor** (final common pathway of platelet aggregation)
- Most potent antiplatelet effect

**Drugs**:
- **Abciximab** (ReoPro): Monoclonal antibody, irreversible, long duration
- **Eptifibatide** (Integrilin): Small molecule, reversible, short duration
- **Tirofiban** (Aggrastat): Small molecule, reversible, short duration

**Clinical Use**:
- **High-risk PCI** (especially STEMI)
- **IV only**
- **Short-term use** (hours)
- Largely replaced by potent P2Y12 inhibitors

**Adverse Effects**:
- **Bleeding** (significant)
- **Thrombocytopenia**

**Clinical Pearl**: Rescue therapy for high-risk PCI; rarely used now

### Dipyridamole

**Mechanism**:
- Inhibits phosphodiesterase
- ↑cAMP in platelets
- Inhibits platelet aggregation

**Clinical Use**:
- **Stroke prevention** (with aspirin = Aggrenox)
- Less effective than clopidogrel

**Adverse Effects**:
- Headache (common)
- Dizziness
- GI upset

---

## Dual Antiplatelet Therapy (DAPT)

**Definition**: Aspirin + P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor)

**Indications**:
1. **Acute coronary syndrome**
2. **Post-PCI with stent**

**Duration**:
- **BMS (bare metal stent)**: Minimum 1 month
- **DES (drug-eluting stent)**: 6-12 months (standard)
  - Extend to 30 months if high ischemic risk, low bleed risk
- **ACS**: 12 months minimum (regardless of stent)

**Premature Discontinuation**:
- **Stent thrombosis risk** (especially DES)
- Coordinate with cardiology before elective procedures

---

## Clinical Pearls - Summary

1. **Arterial thrombosis**: Antiplatelet drugs (aspirin, P2Y12 inhibitors)
2. **Venous thrombosis**: Anticoagulants (warfarin, heparins, DOACs)
3. **Warfarin**: Requires monitoring (INR), many interactions, reversible
4. **DOACs**: No monitoring, fewer interactions, specific reversal limited
5. **Mechanical valves**: Warfarin only (DOACs contraindicated)
6. **Pregnancy**: Heparin/LMWH safe; warfarin/DOACs contraindicated
7. **HIT**: Stop all heparin, use alternative anticoagulant
8. **DAPT duration**: Individualize based on ischemic vs. bleeding risk
9. **Clopidogrel**: Genetic variability; consider alternatives
10. **Bleeding**: Holds, reversal agents, supportive care

---

## Key Takeaways

1. **Antiplatelet drugs** for arterial thrombosis (ACS, stroke, PAD)
2. **Anticoagulants** for venous thromboembolism and AF
3. **Warfarin** requires INR monitoring, has extensive interactions
4. **DOACs** are convenient but contraindicated in mechanical valves
5. **Heparin** safe in pregnancy and renal failure; risk of HIT
6. **LMWH** allows outpatient treatment; dose adjust in renal failure
7. **Aspirin** cornerstone of antiplatelet therapy
8. **DAPT** essential post-PCI; duration individualized
9. **Bleeding risk** major concern with all antithrombotic therapy
10. **Reversal agents** available for most drugs (warfarin, heparin, dabigatran, Xa inhibitors)

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease
4. 2017 ACC Expert Consensus Decision Pathway on DAPT
5. Chest Guidelines: Antithrombotic Therapy for VTE Disease, 2021
6. PLATO Trial: Ticagrelor vs. Clopidogrel in ACS. NEJM 2009.
